Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivablesReceivables - NetShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Receivables - Other (2016 - 2024)

Historic Receivables - Other for Sanofi (SNY) over the last 10 years, with Q4 2024 value amounting to $1.5 billion.

  • Sanofi's Receivables - Other fell 81.98% to $1.5 billion in Q4 2024 from the same period last year, while for Dec 2024 it was $1.5 billion, marking a year-over-year decrease of 81.98%. This contributed to the annual value of $1.5 billion for FY2024, which is 134.95% down from last year.
  • Latest data reveals that Sanofi reported Receivables - Other of $1.5 billion as of Q4 2024, which was down 81.98% from $1.6 billion recorded in Q4 2023.
  • In the past 5 years, Sanofi's Receivables - Other registered a high of $1.6 billion during Q4 2023, and its lowest value of $676.0 million during Q4 2020.
  • For the 5-year period, Sanofi's Receivables - Other averaged around $1.2 billion, with its median value being $1.3 billion (2022).
  • In the last 5 years, Sanofi's Receivables - Other plummeted by 1690.52% in 2020 and then surged by 4280.63% in 2022.
  • Over the past 5 years, Sanofi's Receivables - Other (Quarter) stood at $676.0 million in 2020, then soared by 36.22% to $920.9 million in 2021, then surged by 42.81% to $1.3 billion in 2022, then rose by 18.47% to $1.6 billion in 2023, then decreased by 0.82% to $1.5 billion in 2024.
  • Its Receivables - Other stands at $1.5 billion for Q4 2024, versus $1.6 billion for Q4 2023 and $1.3 billion for Q4 2022.